Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 112 results found since Jan 2013.

Abstract P5-04-17: From transcriptome meta-analysis to targeted therapies in triple negative breast cancer
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that urgently requires the identification and approval of novel targeted therapies. Even for breast cancer subtypes that have approved targeted therapies such as tamoxifen in ER+ and herceptin in HER2+ patients, there are a proportion of patients that do not respond to these therapies or develop resistance and succumb to metastatic recurrence. Thus, there is a clinical need to identify patients who do not benefit from current standard therapies and developing new strategies for therapy for non-responsive patients across all breast cancer subtypes.We hypothe...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Rozali, E., Al-Ejeh, F. Tags: Poster Session Abstracts Source Type: research

Abstract P3-04-02: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine response and estrogen signaling are not well understood in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Based on these observations, we hypothesize that ER regulates unique signaling pathways in ILC cells that control growth and endocrine response.To identi...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Sikora, M., Oesterreich, S. Tags: Poster Session Abstracts Source Type: research

Abstract C150: High expression of SNAI2 is associated with the emergence of a highly motile fulvestrant-resistant phenotype and is an indicator of poor response to endocrine treatment in estrogen receptor-positive metastatic breast cancer
Endocrine resistance is a major clinical problem and is associated with the acquisition of aggressive tumor spread and invasion. To investigate the association between endocrine resistance and tumor cell migration and invasion, we evaluated a panel of MCF7-based cell line models resistant to either tamoxifen, aromatase inhibitors or fulvestrant. Fulvestrant-resistant cell lines showed a significantly higher migration capacity than the parental fulvestrant-sensitive cell line. Gene expression profiling and data analysis using Ingenuity Pathway Analysis (IPA) of these fulvestrant-resistant/fulvestrant-sensitive cell lines id...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Alves, C. L., Elias, D., Lyng, M., Bak, M., Lykkesfeldt, A. E., Ditzel, H. J. Tags: Target Identification and Validation: Poster Presentations - Proffered Abstracts Source Type: research

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients
Abstract Aromatase inhibitors (AI), either alone or together with chemotherapy, have become the standard adjuvant treatment for postmenopausal, estrogen receptor-positive (ER+) breast cancer. Although AIs improve overall survival, resistance is still a major clinical problem, thus additional biomarkers predictive of outcome of ER+ breast cancer patients treated with AIs are needed. Global gene expression analysis was performed on ER+ primary breast cancers from patients treated with adjuvant AI monotherapy; half experienced recurrence (median follow-up 6.7 years). Gene expression alterations were validated by qR...
Source: Breast Cancer Research and Treatment - November 19, 2015 Category: Cancer & Oncology Source Type: research

Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
Abstract Development of new therapeutic strategies is becoming increasingly important to overcome tamoxifen resistance. Recently, much interest has been focused on anti-tumor effects of metformin commonly used to treat type II diabetes. Increased protein expression and signaling of epidermal growth factor receptor (EGFR) family is a possible mechanism involved in tamoxifen resistance. Since HER2/HER3 heterodimers are able to induce strong downstream signaling and activate various biological responses such as cellular proliferation and growth, we investigated the anti-cancer effect of metformin by inhibition of sig...
Source: Tumor Biology - November 18, 2015 Category: Cancer & Oncology Source Type: research

Abstract 068: Role for the Rho-GAP Graf3 in the Pathogenesis of Human Hypertension Session Title: Concurrent XIV B: Vascular Biology I
Activation of RhoA in vascular smooth muscle cells (SMC) has been linked to vasoconstrictor-induced hypertension (HTN), but the relevance of this pathway to human disease was undetermined. We identified GRAF3 as a RhoA-GAP expressed specifically in SMC in mice and humans and reported that global GRAF3-deficient mice exhibited significant basal HTN (+ 25 mm Hg) that was fully reversed by treatment with a Rho-kinase inhibitor (Nature Comm. 2013;4:2910). Importantly, we recently created a tamoxifen inducible SMC-GRAF3 re-expression model which resulted in a near complete reversal of MAP (from 123 mmHg to 95 mm Hg), indicating...
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Bai, X., Mangum, K., Mack, C., Taylor, J. M. Tags: Session Title: Concurrent XIV B: Vascular Biology I Source Type: research

Chaperone gp96 mediates ER-α36 cell membrane expression.
In this study, we investigated the role of cell membrane glycoprotein 96 (mgp96) in the regulation of ER-α36 expression and signaling. We found that the C-terminal domain of mgp96 directly interacts with ER-α36 on the cell membrane of breast tumor cells. This interaction stabilizes the ER-α36 protein, thereby increasing its signaling, which, in turn, increases tumor cell growth and invasion. Moreover, targeting mgp96 with siRNA or monoclonal antibody (mAb) blocks the mgp96-ER-α36 interaction and inhibits breast cancer growth and invasion both in vitro and in vivo. These results provide insights into the modulation of c...
Source: Oncotarget - September 26, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells.
Authors: Ma G, Pan Y, Zhou C, Sun R, Bai J, Liu P, Ren Y, He J Abstract Tamoxifen resistance is a major clinical problem for ER-positive breast cancer, but the underlying mechanism is not completely elucidated. In the present study, we reported that mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1), a member of the family of MKPs, is involved in tamoxifen resistance. We found that MKP1 expression increased in tamoxifen resistant MCF7 cells. To explore the possible role of MKP1 in tamoxifen resistance, siRNA targeting MKP1 was transfected into tamoxifen resistant MCF7 cells. To our surprise, knockdown...
Source: Oncology Reports - September 6, 2015 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Phosphoproteomic analysis identifies FAK2 as a potential therapeutic target for tamoxifen resistance in breast cancer.
Abstract Tamoxifen, an estrogen receptor-α (ER) antagonist, is an important agent for the treatment of breast cancer. However, this therapy is complicated by the fact that a substantial number of patients exhibit either de novo or acquired resistance. To characterize the signaling mechanisms underlying this resistance, we treated the MCF7 breast cancer cell line with tamoxifen for over six months and showed that this cell line acquired resistance to tamoxifen in vitro and in vivo. We performed SILAC-based quantitative phosphoproteomic profiling on the tamoxifen resistant and vehicle-treated sensitive cell lines t...
Source: Molecular and Cellular Proteomics : MCP - September 1, 2015 Category: Molecular Biology Authors: Wu X, Zahari MS, Renuse S, Nirujogi RS, Kim MS, Manda SS, Stearns V, Gabrielson E, Sukumar S, Pandey A Tags: Mol Cell Proteomics Source Type: research

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13
Conclusions: We show that the PKA-anchoring protein AKAP13 is essential for the phosphorylation of ERαS305, which leads to tamoxifen resistance both in cell lines and tamoxifen-treated breast cancer patients.
Source: BMC Cancer - August 14, 2015 Category: Cancer & Oncology Authors: Cristiane Bentin ToaldoXanthippi AlexiKarin BeelenMarleen KokMichael HauptmannMaurice JansenEls BernsJacques NeefjesSabine LinnRob MichalidesWilbert Zwart Source Type: research

Abstract 4095: Protein kinase C alpha (PKC{alpha}) is a novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast cancer
In this study, two representative cell lines, HCC1937 and HCC1143, were chosen to investigate the relationship between PKCα, FOXC2, and p120-catenin, and how their interplay alters migration and invasion of TNBC and endocrine resistant breast cancer.Cell lines (T47D:A18/PKCα, HCC1143, HCC1937) were maintained as previously described and according to ATCC guidelines. Expression of PKCα and FOXC2 were manipulated using siRNA targeting PKCα and FOXC2 respectively. Transcripts level of FOXC2 (FOXC2) and CTNND1(p120-catenin) were measured using quantitative PCR. PKCα, FOXC2, and p120-catenin protein expression was measured...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Pham, T. N., Perez-White, B., Tonetti, D. A. Tags: Tumor Biology Source Type: research

FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells.
Authors: Halacli SO, Dogan AL Abstract Loss of Forkhead box P1 (FOXP1) protein expression confers a poor prognosis in sporadic and familial breast cancer patients, and the FOXP1 gene maps to a tumor suppressor locus at chromosome 3p14. Although correlation studies have indicated that FOXP1 has a role in tumor suppression, determination of the regulatory mechanism of FOXP1 is required to establish its function in breast cancer. It has previously been identified that FOXP1 is regulated by estrogen in breast cancer and that treatment with bisphenol A is effective for regulating the transformation of the normal human b...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

17β-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells
Conclusions: This study illustrates for the first time that, in contrast to hepatic and adipose tissue, estrogen induces SCD-1 expression and activity in breast carcinoma cells. These results support SCD-1 as a therapeutic target in estrogen-sensitive breast cancer.
Source: BMC Cancer - May 29, 2015 Category: Cancer & Oncology Authors: Anissa BelkaidSabrina DuguayRodney OuelletteMarc Surette Source Type: research

UCP2 inhibition sensitizes breast Cancer cells to therapeutic agents by increasing oxidative stress.
In conclusion, UCP2 could be a therapeutic target in breast cancer, especially in those patients treated with tamoxifen. PMID: 25960046 [PubMed - as supplied by publisher]
Source: Free Radical Biology and Medicine - May 7, 2015 Category: Biology Authors: Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A, Oliver J, Roca P Tags: Free Radic Biol Med Source Type: research

Abstract P3-04-05: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are ER-positive, however, endocrine response and estrogen signaling are not well described in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than similar invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Additionally, we recently identified ILC-specific ER-target genes and de novo tamoxifen resistance driven by ER in ILC model systems. Based on these observations, we ...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Sikora, M. J., Bahreini, A., Alexander, C. M., Oesterreich, S. Tags: Poster Session Abstracts Source Type: research